SSII's surgical robot adoption accelerates; losses and financing remain the drag
Installed base and procedure volumes keep climbing SSi Mantra systems installed rose to 244 by late September, up 45% from end-2025, with 14,503 cumulative procedures and 195 telesurgeries. More machines placed and more surgeries done means more recurring revenue and proof the robot works, which supports the stock.
This is the core demand engine behind SSII's growth story this period.
Record quarterly sales and a beat on installations Q2 revenue hit $13.9 million, up 39% year over year, with 30 systems installed versus the 25 analysts expected and procedures up 143%. Beating expectations on both sales and placements tells investors the business is scaling faster than thought, lifting the stock.
It shows the financial results that validate the adoption trend.
New markets and training widen the runway SSII launched Sri Lanka's first robotic cardiac program, added programs in Colombia and India, and graduated 33 surgeons from seven countries in its first cardiac training class. Training doctors and opening new countries builds future demand and locks in the SSi Mantra ecosystem.
Geographic and clinical expansion is a fresh driver of future sales.
Strong growth but still losing money and needing cash Zacks started coverage with a Neutral rating, noting first-half revenue of $25 million and gross profit of $12.4 million, but also a $6.2 million net loss, reliance on outside financing, and tough competition. Growth is real, but profits and funding needs cap the upside for now.
It is the main counterweight investors must weigh against the growth story.